| Literature DB >> 29724887 |
Lijun Xu1, Qianqian Pang1, Yan Jiang1, Ou Wang1, Mei Li1, Xiaoping Xing1, Weibo Xia2.
Abstract
class="Disease">Hypophosphatasia (HPP) is a rareEntities:
Keywords: ALPL gene; HPP; TNSALP
Mesh:
Substances:
Year: 2018 PMID: 29724887 PMCID: PMC6131208 DOI: 10.1042/BSR20171377
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Clinical characteristics of the patients and their families
| FM1-1 | FM1-2 | FM2-1 | FM2-2 | FM3-1 | FM4-1 | FM4-2 | FM5-1 | PA-6 | PA-7 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Phenotype | Odonto | Odonto | Childhood | adult | childhood | odonto | adult | childhood | adult | adult |
| Age of onset (ys) | 1 | 1 | 8 mons | 31 | 1 | 1 | NA | 7 | 33 | 53 |
| Gender (F/M) | F | M | F | F | M | M | M | M | M | F |
| Height (cm) | 111.4 (6 y) (≤1SD) | NA | 118 (8 y) (≤3SD) | NA | 160.5 (15 y) (≤2SD) | NA | NA | 166 (43 y) (≤1SD) | 161 (39 y) (≤2SD) | 150 (57 y) (≤2SD) |
| Serum ALP (U/l) | 22 (58–400) | 29 (58–400) | 6 (30–120) | 28 (30–120) | 26 (58–400) | 17 (58–400) | 29 (30–120) | negative | 23 (30–120) | 13 (30–120) |
| L2–L4 (g/cm2) (T/Z score) | NA | NA | 0.504 (0.6)* | NA | 0.500 (−1.5)* | NA | NA | 0.711 (−3.2)† | 0.911 (−1.6)† | 0.961 (−1.5)† |
| Femoral neck (g/cm2) (T/Z score) | NA | NA | 0.560 (0.63)* | NA | 0.401 (−3.74)* | NA | NA | 0.427 (−4.2)† | 0.570 (−3.1)† | 0.763 (−1.4)† |
| Total hip (g/cm2) (T/Z score) | NA | NA | 0.506 (−0.15)* | NA | 0.363 (−4.53)* | NA | NA | 0.401 (−4.5)† | 0.714 (−2.1)† | 0.928 (−0.4)† |
| Early deciduous tooth loss | Yes | Yes | Yes | No but sparse teeth | Yes | Yes | No but sparse teeth | Yes | No | No |
| History of fracture | No | No | No | No | Yes (once) | No | No | Yes (three times) | No | No |
| Severity of rickets/ osteomalacia | No | No | Moderate | No | Severe | No | No | Extremely severe | No | No |
| Bone deformity | No | No | Yes (rachitic chest) | No | Yes (rachitic rosary, enlargement of wrists, scoliosis, subluxation of the bilateral hip) | No | No | Yes (rachitic chest, valgum deformity of right genu) | No | No |
| Calcium pyrophosphate dihydrate deposition disease (CPPD) | No | No | No | No | Yes | No | No | Yes (stiffness of the left knee-joint) | Yes (pain in arthrosis; calcific periarthritis) | Yes (pain in left shoulder, wrists and elbows) |
| Skeletal hyperostosis | No | No | No | Yes (slight skeletal hyperostosis in both knee joints) | No | Yes (cortical thickening in fibula and tibia bone) | Yes (cervical bone hyperostosis) | No | Yes (vertebral hyperotosis) | Yes (hyperostosis at thoracic and lumbar vertebra) |
The patient from family was indicated in FM; the sporadic patient was indicated in PA. Abbreviation: NA, not available. ys, years. mons, months
*, The Z scores at L1–L4, femoral neck and total hip of young patients were calculated by comparison with the age-specific BMD reference value of Chinese children and adolescents.
†, The T scores at L1–L4, femoral neck and total hip of adult patients were calculated by comparison with the age- and sex-match adult.
Figure 1The clinic characteristics and radiographic signatures of the HPP patients.
(a,b) Early deciduous teeth loss of FM1-1 and FM2-1. (a) FM1-1 had only two maxillary canines left at 6 years of age; (b) FM2-1 had only eight primary teeth left at 8 years of age. The permanent teeth present were all molars. (c) Pectus excavatum of FM2-1; (d) sparse teeth of FM2-2; (e) radiographs of both knees of FM2-2 showed slight skeletal hyperostosis; (f) radiographic examination of FM3-1 showed signs of rickets in the distal ulna and radius; (g) the anteroposterior of the pelvis of FM3-1 showed subluxation of the bilateral hip (red arrow) and calcium deposition adjacent to the great trochanter of the left femur (white arrow); (h) X-ray examination of FM4-1demonstrated cortical thickening in fibula and tibia bone; (i) early deciduous teeth loss of FM5-1. The permanent teeth present were all lower incisors and lower molars, and the lower molars displayed hypocalcified enamel; (j) fracture lines of humerus and femur of FM5-1; (k) bone scan of FM5-1 showed multiple areas of increased tracer uptake in the skull, ribs, and femurs.
Laboratory findings of the six families and three patients with HPP
| FM1-1 | FM1-2 | FM2-1 | FM2-2 | FM3-1 | FM4-1 | FM4-2 | FM5-1 | PA-6 | PA-7 | Reference value | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Serum calcium (mmol/l) | 2.45 | 2.68 | 2.38 | 2.48 | 2.52 | NA | 2.33 | 2.14 | 2.48 | 2.13–2.70 | |
| Serum phosphate (mmol/l) | 1.26† | 1.89* | 1.82* | NA | 1.43† | 1.11† | 1.19† | 1.29–1.94* | |||
| 0.81–1.45† | |||||||||||
| Serum ALP (U/l) | 58–400* | ||||||||||
| 30–120† | |||||||||||
| Serum 25 (OH)D (ng/ml) | NA | NA | 30.7 | NA | 10 | 17.3 | NA | 23.3 | 15.9 | 13.7 | 8–50 |
| Serum 1,25(OH)2D (pg/ml) | NA | 34.29 | NA | NA | NA | NA | 47.37 | 53.87 | NA | 19.6–54.3 | |
| Serum iPTH (pg/ml) | 16.6 | 49.2 | 54 | NA | 31.4 | 31.9 | 43.4 | 15–65 | |||
| 24-h urine calcium (mmol) | 0.41 | NA | 1.60 | NA | 4.64 | 2.78 | NA | 3.29 | 6.53 | 3.39 | 2.5–7.5 |
| Nephrocalcinosis | no | NA | no | NA | no | no | NA | no | yes | no |
Abnormal results were indicated in bold. Abbreviation: NA, not available.
*, Indicated the normal range for serum phosphate, serum ALP in patients from 2 to 18 years old are 1.29–1.94 mmol/l, 58–400 U/l.
†, Indicated the normal range for serum phosphate, serum ALP in adult patient are 0.81–1.45, 30–120 U/l .
‡, Phosphatase value was negative in FM5-1 after repeated measurement.
Mutations in the ALPL gene found in the six families and three patients
| Number | Relationship | Amino acid change | Status | Location of mutated amino acids in 3D model | Function Predict (Polyphen2, SIFT, Mutation Assessor) | Reference |
|---|---|---|---|---|---|---|
| FM1-1 | Proband | T141N | Compound heterozygous | Active site | Damaging | [ |
| C497S* | Not shown | Damaging | The present study | |||
| FM1-2 | Proband’s brother | T141N | Compound heterozygous | Active site | Damaging | [ |
| C497S* | Not shown | Damaging | The present study | |||
| FM1-3 | Proband’s mother | T141N | Heterozygous | Active site | Damaging | |
| FM1-4 | Proband’s father | C497S* | Heterozygous | Not shown | Damaging | The present study |
| FM2-1 | Proband | Y388H | Heterozygous | Crown domain | Damaging | [ |
| FM2-2 | Proband’s mother | Y388H | Heterozygous | Crown domain | Damaging | 12 |
| FM3-1 | Proband | R138Pfs45x* | Frameshift | - | - | The present study |
| FM4-1 | Proband | R136H | Compound heterozygous | Active site | Damaging | 30 |
| R136C | Active site | Damaging | Versailles lab, October 2003 | |||
| FM4-2 | Proband’s father | R136H | Heterozygous | Active site | Damaging | 30 |
| FM5-1 | Proband | I10T | Compound heterozygous | Not shown | Benign | Versailles lab, June 2017 |
| 328delF | Homodimer interface | - | 25 | |||
| V459A* | Heterozygous | Homodimer interface | Damaging | The present study | ||
| C201R* | Heterozygous | - | Damaging | The present study |
Accession number genomic sequence of the ALPL gene: Ref Seq NG_008940.1. Function predict by PolyPhen2 software, score ranges from 0 to 1.000, where 0 is benign, and a high positive number is damaging.
*, Novel mutations in ALPL.
Figure 2Genetic analysis of ALPL in the probands and their relatives.
Black symbols represent the affected individuals, open symbols with a point represent the carriers, and open symbols represent the unaffected individuals. Circles and squares indicate the females and males, respectively.
Figure 3Three dimensional models of TNSALP monomer.
The model was based on the crystal structure of the PLAP monomer (PDB ID: 1E2W). The crown domain was indicated by red. The magnesium ion was showed by gray ball. The single heterozygous mutations found in the present study located in the active site (T141), the crown domain (Y388), and the homodimer interface (F328, V459) were highlighted in purple, respectively.
Primer sequences used to amplify the 12 ALPL gene.